Physician profile
Michael Uzer
NPI 1295733475
$1,706.63
in general payments reported to CMS, 2019-2025
13 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $73.53 · 2021: $186 · 2022: $378 · 2023: $456 · 2024: $279 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.67 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $162.06 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $124.20 | 2021-2024 | Stelara |
| Gilead Sciences, INC. | $115.05 | 2019-2025 | |
| Ucb, INC. | $63.93 | 2019-2020 | |
| Celgene Corporation | $49.37 | 2023 | Zeposia |
| Beckman Coulter, INC. | $47.68 | 2021 | |
| Qol Medical, LLC | $32.89 | 2023 | Sucraid |
| Ardelyx, INC. | $23.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.66 | 2022 | |
| Intercept Pharmaceuticals, INC. | $12.38 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $11.98 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Uzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.